Heron Therapeutics Inc. (HRTX) Receives New Coverage from Analysts at Brean Capital
Brean Capital assumed coverage on shares of Heron Therapeutics Inc. (NASDAQ:HRTX) in a research note published on Tuesday. The brokerage issued a buy rating and a $41.00 price target on the biotechnology company’s stock.
A number of other research firms have also recently weighed in on HRTX. Leerink Swann reaffirmed an outperform rating and set a $33.00 price objective on shares of Heron Therapeutics in a research report on Thursday, August 18th. Cantor Fitzgerald reissued a buy rating and set a $38.00 target price on shares of Heron Therapeutics in a research note on Tuesday, August 9th. Zacks Investment Research downgraded Heron Therapeutics from a hold rating to a sell rating in a research note on Wednesday, August 3rd. JMP Securities reissued a buy rating on shares of Heron Therapeutics in a research note on Friday, September 9th. Finally, Cowen and Company reissued a buy rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $42.14.
Heron Therapeutics (NASDAQ:HRTX) traded up 2.262% during trading on Tuesday, reaching $16.454. The company’s stock had a trading volume of 148,211 shares. The company has a 50 day moving average price of $18.97 and a 200-day moving average price of $18.92. Heron Therapeutics has a 52 week low of $15.13 and a 52 week high of $31.32.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21. Analysts forecast that Heron Therapeutics will post ($4.44) EPS for the current year.
In other news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the sale, the insider now owns 102,640 shares in the company, valued at $2,391,512. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 20.31% of the company’s stock.
Several large investors have recently bought and sold shares of HRTX. BlackRock Group LTD boosted its stake in Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 897 shares during the period. Parametric Portfolio Associates LLC acquired a new stake in Heron Therapeutics during the second quarter valued at about $213,000. BlackRock Advisors LLC boosted its stake in Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 1,769 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock valued at $302,000 after buying an additional 1,283 shares during the period. Finally, American International Group Inc. boosted its stake in Heron Therapeutics by 8.1% in the second quarter. American International Group Inc. now owns 18,293 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 1,369 shares during the period.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.